Drug companies seek MS patients to lobby for new products

BMJ 2000; 320 doi: (Published 22 January 2000) Cite this as: BMJ 2000;320:207
  1. Gavin Yamey
  1. BMJ

    Schering Health Care, the manufacturer of the multiple sclerosis treatment Betaferon (interferon beta), is seeking the support of patients to lobby the National Institute for Clinical Excellence (NICE) before its ruling on the drug in May. The drug costs about £10000 ($16000) a year per patient, and many health authorities have been reluctant to …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to to receive unlimited access to all content on for 14 days.
    Sign up for a free trial